These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10220594)

  • 1. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Fundamentals of economic analysis.
    Mark DB; Simons TA
    Am Heart J; 1999 May; 137(5):S38-40. PubMed ID: 10220594
    [No Abstract]   [Full Text] [Related]  

  • 2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective.
    Kessler JM
    Am Heart J; 1999 May; 137(5):S111-4. PubMed ID: 10220610
    [No Abstract]   [Full Text] [Related]  

  • 3. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data.
    Mark DB; Simons TA
    Am Heart J; 1999 May; 137(5):S123-5. PubMed ID: 10220613
    [No Abstract]   [Full Text] [Related]  

  • 4. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. The value of cost-effectiveness analyses for reimbursement decisions: perspectives from Medicare.
    Sheingold SH
    Am Heart J; 1999 May; 137(5):S81-6. PubMed ID: 10220604
    [No Abstract]   [Full Text] [Related]  

  • 5. Will Bundled Payments Change Health Care? Examining the Evidence Thus Far in Cardiovascular Care.
    Shih T; Chen LM; Nallamothu BK
    Circulation; 2015 Jun; 131(24):2151-8. PubMed ID: 26078370
    [No Abstract]   [Full Text] [Related]  

  • 6. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis.
    DeLong ER; Simons T
    Am Heart J; 1999 May; 137(5):S47-50. PubMed ID: 10220596
    [No Abstract]   [Full Text] [Related]  

  • 7. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful economic study? The health systems perspective.
    Lee TH
    Am Heart J; 1999 May; 137(5):S67-70. PubMed ID: 10220600
    [No Abstract]   [Full Text] [Related]  

  • 8. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective.
    Jackson JD
    Am Heart J; 1999 May; 137(5):S105-10. PubMed ID: 10220609
    [No Abstract]   [Full Text] [Related]  

  • 9. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. A survey of standards and guidelines for cost-effectiveness analysis in health care.
    Stewart A; Schmier JK; Luce BR
    Am Heart J; 1999 May; 137(5):S53-61. PubMed ID: 10220598
    [No Abstract]   [Full Text] [Related]  

  • 10. The economics of cardiovascular disease in the United States.
    Chen J; Rizzo JA
    Crit Care Clin; 2012 Jan; 28(1):77-88, vi. PubMed ID: 22123100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Payment changes in CV imaging.
    Weissman NJ
    JACC Cardiovasc Imaging; 2013 Aug; 6(8):927-8. PubMed ID: 23948385
    [No Abstract]   [Full Text] [Related]  

  • 12. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of government agencies regarding cost-effectiveness claims: FDA perspective.
    Temple R
    Am Heart J; 1999 May; 137(5):S75-7. PubMed ID: 10220602
    [No Abstract]   [Full Text] [Related]  

  • 13. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Product labeling and pharmacoeconomic information.
    Morris LA
    Am Heart J; 1999 May; 137(5):S78-80. PubMed ID: 10220603
    [No Abstract]   [Full Text] [Related]  

  • 14. A Pathway Through the Bundle Jungle.
    Polite B; Ward JC; Cox JV; Morton RF; Hennessy J; Page R; Conti RM
    J Oncol Pract; 2016 Jun; 12(6):504-9. PubMed ID: 27173604
    [No Abstract]   [Full Text] [Related]  

  • 15. Perspectives. Quality, output gains belie some health cost estimates.
    Cunningham R
    Med Health; 1998 Feb; 52(5):suppl 1-4. PubMed ID: 10176633
    [No Abstract]   [Full Text] [Related]  

  • 16. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Consortium perspective: what constitutes a useful economic study?
    Chen C; Vlasses PH
    Am Heart J; 1999 May; 137(5):S71-4. PubMed ID: 10220601
    [No Abstract]   [Full Text] [Related]  

  • 17. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials.
    Hlatky MA
    Am Heart J; 1999 May; 137(5):S41-6. PubMed ID: 10220595
    [No Abstract]   [Full Text] [Related]  

  • 18. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Terminology I would like to see disappear.
    Detsky AS
    Am Heart J; 1999 May; 137(5):S51-2. PubMed ID: 10220597
    [No Abstract]   [Full Text] [Related]  

  • 19. Heavy Heart: The Economic Burden of Heart Disease in the United States Now and in the Future.
    Foy AJ; Mandrola JM
    Prim Care; 2018 Mar; 45(1):17-24. PubMed ID: 29406942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy.
    Schrogie JJ
    Am Heart J; 1999 May; 137(5):S126-8. PubMed ID: 10220614
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.